On Monday, Viking Therapeutics (NASDAQ:VKTX), now valued at $5.9 billion after surging over 300% in the past year, received a new Overweight rating from Piper Sandler, with a price target set at $74.00. According to InvestingPro data, analyst targets for the stock range from $80 to $164.
The firm highlighted the promising results of Viking's Phase 2 study for its weight loss drug candidate, VK2735. The treatment demonstrated a compelling weight loss profile along with lower patient discontinuation rates in obese individuals. While the company is not yet profitable, InvestingPro analysis shows it maintains a strong financial position with a remarkable current ratio of 36.47 and more cash than debt on its balance sheet.
The analyst at Piper Sandler noted the potential of VK2735 as a leading oral incretin therapy. The drug has shown fewer gastrointestinal adverse events and comparable efficacy to its competitors in the incretin space. The firm also emphasized the encouraging data suggesting that higher doses of VK2735 could lead to increased weight loss, which is significant in the highly lucrative obesity market.
Viking Therapeutics is also advancing its pipeline with VK2809, a drug in development for MASH, having completed Phase 2 trials. The company is moving forward with its amylin agonist program, which is expected to enter Phase 1 trials in 2025. The combination of these programs positions Viking with a diverse portfolio in the obesity and MASH sectors within the small to mid-cap biopharmaceutical industry.
The coverage initiation and price target announcement come as Viking Therapeutics continues to make progress in developing treatments for obesity and metabolic diseases. The company's broad pipeline and the advancement of its various drug candidates are key factors in the positive outlook given by Piper Sandler.
For deeper insights into Viking's financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with detailed analysis and actionable intelligence.
In other recent news, Viking Therapeutics has reported significant progress in its clinical programs.
The company's VK2735 program, aimed at treating obesity and type 2 diabetes, has shown promising results in Phase II and Phase I trials, according to B.Riley, which recently initiated coverage on Viking with a Buy rating. Laidlaw, Jefferies, and BTIG have also maintained their Buy ratings, emphasizing the potential of VK2735 in the obesity treatment market.
Viking Therapeutics has also reported positive results from its Phase 2b clinical trial of VK2809 for treating non-alcoholic steatohepatitis (NASH), achieving significant reductions in liver fat content and improvements in fibrosis. The company's financial results for Q3 2024 revealed a net loss of $24.9 million, with research and development expenses of $22.8 million. However, the company's cash and equivalents remain strong at $930 million, supporting its future clinical trials.
These recent developments underscore Viking Therapeutics' progress in the field of obesity and metabolic disorder medication development. The company is also awaiting updates on competing therapies from Novo Nordisk (NYSE:NVO), Amgen (NASDAQ:AMGN), and Roche, which could further highlight the unique position of Viking's VK2735 in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.